Table 2.
Participants with resistance mutation present at > 1% of total quasispecies population
| Amino acid mutation | Proportion of mutation present, % | Subject number | HIV positive | Estimated duration of infection, weeks |
|---|---|---|---|---|
| Protease (n = 49) | ||||
| Mutation at >50 % | ||||
| V36M | 99.4 | 127 | Y | 25 |
| V55A | 89.6 | 609 | N | 58 |
| V55A | 99.9 | 664 | N | 9 |
| Q80K | 98.5 | 804 | Y | 58 |
| Q80K | 99.2 | 127 | Y | 25 |
| Mutation >1–50 % | ||||
| Q41R | 1.02 | 2403 | Y | 16 |
| V55A | 1.03 | 634 | N | 31 |
| V55A | 1.10 | 628 | Y | 12 |
| Q80R | 1.27 | 2016 | N | 20 |
| A156S | 1.99 | 501 | N | 44 |
| I170T | 1.10 | 2605 | N | 60 |
| I170T | 1.54 | 501 | N | 44 |
| V170A | 1.08 | 120 | Y | 9 |
|
| ||||
| Polymerase (n = 49) | ||||
| Mutation at >50 % | ||||
| M423I | 98 | 803 | N | 57 |
| Mutation >1–50 % | ||||
| S365T | 1.46 | 653 | N | 20 |
| S365T | 2.62 | 620 | Y | 64 |
| S365T | 1.24 | 2003 | N | 29 |
| S365T | 1.38 | 120 | Y | 9 |
| L419M | 1.81 | 1402 | N | 21 |
| L419M | 1.19 | 1001 | N | 74 |
| L419V | 1.47 | 302 | N | 21 |
| M423T | 1.56 | 125 | N | 23 |
| M423T | 1.78 | 609 | N | 58 |
| V494A | 1.10 | 501 | N | 44 |
| V494A | 1.03 | 2402 | Y | 15 |
| P496S | 2.60 | 630 | Y | 30 |
| V499A | 18.8 | 120 | Y | 9 |
|
| ||||
| NS5A (n = 13) | ||||
| Mutation >50 % | ||||
| M28V | 99.5 | 302 | N | 21 |
| Mutation >1–50 % | ||||
| Q30R | 2.29 | 120 | Y | 9 |
| Q30R | 1.33 | 627 | ||
| H58P | 1.10 | 120 | Y | 9 |